Pipeline
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Pipeline
COVID-19 Vaccine
| Pipeline | Antigen gene | Basic research | Preclinical experiment | Phase of Clinical trial | ||
|---|---|---|---|---|---|---|
| Phase Ⅰ | Phase Ⅱ | Phase Ⅲ | ||||
| AdCLD-CoV19-1 | ’SARS-CoV-2 Spike Protein Recombinant gene |
NCT Identifier : NCT04666012
|
||||
| AdCLD-CoV19-1 OMI | ’SARS-CoV-2 B.1.1.529 Recombinant gene |
NCT Identifier : NCT05576623
NCT Identifier : NCT05993325
|
||||
| AdCLD-CoV19-1 LP.8.1 |
SARS-CoV-2 LP.8.1* spike protein Recombinant gene |
|
||||
| AdCLD-CoV19-1 VOC |
SARS-CoV-2 VOC* Spike protein Recombinant gene |
|
||||
LP.8.1: WHO-recommended 2025 COVID-19 vaccine strain (announced on May 15, 2025)
*VOC : Variant of Concern. It refers to a virus designated by the World Health Organization (WHO) among COVID-19 variants that require public health measures due to confirmed negative changes in transmissibility, pathogenicity, and vaccine efficacy.
-
AdCLD-CoV19-1
SARS-CoV-2 Spike protein
Basic research Preclinical experiment Phase Ⅰ Phase Ⅱ Phase Ⅲ NCT Identifier : NCT04666012
- Indication : COVID-19 prevention
- Clinical Trial Stage : Phase IIb Clinical Trial
- Clinical Trial Purpose : To evaluated safety and immunogenicity of AdCLD-CoV19
- Clinical Trial Result : Completed
-
AdCLD-CoV19-1 OMI
SARS-CoV-2 B.1.1.529 spike protein 재조합유전자
Basic research Preclinical experiment Phase Ⅰ Phase Ⅱ Phase Ⅲ NCT Identifier : NCT05576623
- Indication : COVID-19 Omicron prevention
- Clinical Trial Stage : Phase1/2 IIb Clinical Trial
- Clinical Trial Purpose : To evaluated safety and immunogenicity of AdCLD-CoV19 OMI
- Clinical Trial Result : Complete
NCT Identifier : NCT05993325
- Clinical Trial Stage : Phase-III Clinical Trial
- Clinical Trial Purpose : To evaluate safety and immunogenicity of AdCLD-CoV19-1 OMI and comparative assessment with the control vaccine
- Clinical Trial Result : In-progress
-
AdCLD-CoV19-1 LP.8.1
SARS-CoV-2 LP.8.1* spike protein Recombinant gene
Basic research Preclinical experiment Phase Ⅰ Phase Ⅱ Phase Ⅲ -
AdCLD-CoV19-1 VOC
SARS-CoV-2 VOC* Spike protein Recombinant gene
Basic research Preclinical experiment Phase Ⅰ Phase Ⅱ Phase Ⅲ
LP.8.1: WHO-recommended 2025 COVID-19 vaccine strain (announced on May 15, 2025)
*VOC : Variant of Concern. It refers to a virus designated by the World Health Organization (WHO) among COVID-19 variants that require public health measures due to confirmed negative changes in transmissibility, pathogenicity, and vaccine efficacy.
